First-in-Human Experience With Ultra-Low Temperature Cryoablation for Monomorphic Ventricular Tachycardia

Tom De Potter, Jippe C. Balt, Lucas Boersma, Frederic Sacher, Peter Neuzil, Vivek Reddy, Ilya Grigorov, Atul Verma

Research output: Contribution to journalReview articlepeer-review


Ultra-low temperature cryoablation (ULTC) using near-critical nitrogen (−196ºC) has been shown to produce durable, contiguous, transmural lesions in ventricles of animal models. This report summarizes acute experience with ULTC in the first-ever 13 patients with recurrent monomorphic ventricular tachycardias (VTs) of both ischemic cardiomyopathy and nonischemic etiologies enrolled in the CryoCure-VT (Cryoablation for Monomorphic Ventricular Tachycardia; NCT04893317) clinical trial. After an average of 9.6 ± 4.6 endocardial ULTC lesions per patient, no clinical ventricular tachycardias were inducible in 91% of patients. Two procedure-related serious adverse events recorded in 2 patients resolved post-procedurally without clinical sequelae. Further investigation of both acute and chronic outcomes is warranted and ongoing.

Original languageEnglish
Pages (from-to)686-691
Number of pages6
JournalJACC: Clinical Electrophysiology
Issue number5
StatePublished - May 2023


  • ultra-low temperature cryoablation
  • ventricular tachycardia ablation


Dive into the research topics of 'First-in-Human Experience With Ultra-Low Temperature Cryoablation for Monomorphic Ventricular Tachycardia'. Together they form a unique fingerprint.

Cite this